Dymista® provides a 30 minute onset of action in clinical practice

Did you know, Dymista® provides a 30 minute onset of action in clinical practice, with efficacy confirmed in real life

In a randomised, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista® (MP29-02) showed a rapid onset of action, with statistically significantly greater improvement in the total nasal symptom score (TNSS) compared with placebo at 30 minutes after the first dose. The significant improvements in TNSS over placebo were sustained at each subsequent evaluation point during the 4-hour observation period.'

A study assessing the use, effectiveness and safety of Dyrnista® in routine clinical practice reported that the effectiveness of Dyrnista® observed in real-world setting was better than its efficacy in randomised controlled clinical trials. Results show in real-life, a rapid clinically relevant change, the rapid and complete response is what AR patients want.2  Patients (n=1781) assessed symptom control using visual analogue scale (VAS). The study showed that Dyrnista® provides effective and rapid symptom control across all age groups (adolescents >_ 12 years, adults, and older patients) in a real-life setting with responder rates higher than those observed in controlled clinical trials.2

Dymista® provides a 30 minute onset of action in clinical practice1

  • Slide
  • Slide

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
  • Impact
  • Guidelines
  • Clinical Papers
    Clinical Papers


  1. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasonepropionate) in the treatment of seasonal allergic rhinitis: a randomized, double- blind. Placebo-controlled trial of efficacy and safety. Allergy AsthmaProc. 2012; 33: 324-332.
  2. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, el al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real—life: Results from a noninterventional study. Allergy AsthmaProc. 2015; 36: 40-47.

Want to expand your knowledge…

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Viatris Connect

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.


Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.